Creo Medical Group (LON:CREO) Stock Price Down 7.3% – Should You Sell?

Creo Medical Group PLC (LON:CREO)’s share price fell 7.3% on Thursday . The stock traded as low as GBX 13.07 ($0.16) and last traded at GBX 13.08 ($0.17). 532,088 shares traded hands during trading, a decline of 21% from the average session volume of 674,831 shares. The stock had previously closed at GBX 14.10 ($0.18).

Creo Medical Group Stock Performance

The company has a debt-to-equity ratio of 29.96, a quick ratio of 2.19 and a current ratio of 3.24. The stock has a market cap of £61.05 million, a P/E ratio of -281.25 and a beta of 0.86. The business’s 50-day moving average price is GBX 18.30 and its 200-day moving average price is GBX 26.60.

Insider Buying and Selling at Creo Medical Group

In other Creo Medical Group news, insider Richard John Rees bought 98,000 shares of the firm’s stock in a transaction that occurred on Thursday, October 24th. The shares were bought at an average price of GBX 20 ($0.25) per share, with a total value of £19,600 ($24,738.10). Also, insider Kevin Crofton bought 2,916,666 shares of the stock in a transaction dated Monday, October 21st. The stock was bought at an average cost of GBX 24 ($0.30) per share, for a total transaction of £699,999.84 ($883,503.52). 22.43% of the stock is currently owned by corporate insiders.

About Creo Medical Group

Creo Medical Group PLC, through its subsidiaries, researches, develops, manufactures, and sells medical devices and instruments in the United Kingdom. It is developing CROMA, an energy platform that combines bipolar radiofrequency for precise localized cutting and microwave energy for controlled coagulation, to provide physicians with flexible, accurate, and highly controllable devices delivered through a flexible endoscope.